Navigation Links
DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
Date:4/16/2008

SAN MATEO, Calif., April 16 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, announced today that after completing its review of safety and efficacy data currently available, an independent Data Safety Monitoring Board (DSMB) has recommended that Anthera's Phase II clinical trial, known as the IMPACTS (Investigation of the Modulation of Phospholipase in Acute ChesT Syndrome) Study can continue under the current protocol, without change.

IMPACTS is a Phase II multi-center clinical trial evaluating the safety and effectiveness of intravenous A-001 (varespladib sodium) in preventing the development of acute chest syndrome in hospitalized sickle cell disease patients. Enrolled patients are at-risk for acute chest syndrome based on the combination of pain (vaso-occlusive crisis), fever, and elevated serum level of the enzyme (secretory phospholipase).

"We are pleased with the DSMB's response and look forward to continuing the A-001 trial under our original protocol," said Dr. James E. Pennington, M.D., Executive Vice President and Chief Medical Officer of Anthera Pharmaceuticals, Inc. "Treatment options are limited for this important patient population and we believe a drug that provides an opportunity for early intervention would help address a significant unmet medical need."

"Today's announcement marks another exciting milestone for Anthera," said Paul F. Truex, President and Chief Executive Officer of Anthera Pharmaceuticals, Inc. "Over the past few months, we've also made significant progress in our A-002 program for cardiovascular disease. In February, we completed our end of Phase II meeting with the FDA. In early April, we completed a pre-submission meeting with European Medicines Agency (EMEA). Presently, we are preparing to submit our registration protocols to FDA as part of the Special Protocol Assessment process."

About A-001

A-001 is a poten
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Fifth DSMB Meeting Supports Neurobiological Technologies Continuation of Phase 3 Stroke Trials With Viprinex(TM) (ancrod)
2. Karmanos Cancer Institute Research Supports Role of Inflammation to Determine Lung Cancer Risk, Particularly in African-American Women
3. DSMB Supports Continuation of Phase 3 AGENDA Trial of Genasense(R) in Advanced Melanoma
4. DSMB Again Supports Continuation of the Phase III Clinical Trial of Medidur(TM) FA for the Treatment of DME
5. Evanston Northwestern Healthcare Researchers Explain Effects of Large-Scale, Universal MRSA Surveillance Program That Supports Expanded Intervention
6. ACR Supports American Cancer Society Inclusion of CT Colonography (Virtual Colonoscopy) as Recommended Screening Tool for Colorectal Cancer in New Screening Guidelines
7. New Clinical Data Further Supports Chromium Picolinates Role in Enhancing Brain Activity in Older Adults
8. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
9. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
10. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
11. Interim Safety Analysis Supports Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... PALM BEACH GARDENS, Fla. , Jan. 15, 2014  In an ... C. difficile and TB in ambulances and other transport vehicles, an ... being used by rescue personnel for the first time. ... coming in contact with these deadly pathogens, West Palm ...
(Date:1/15/2014)... 2014  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ... System as a non-invasive, wireless continuous glucose monitoring system, ... Chairman and Interim CEO of Echo Therapeutics, will present ... Conference. Mr. Doman will make a ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... & Forecast – Worldwide Analysis ... Pump Market Analysis ...
Breaking Medicine Technology:Superbugs No Longer Ride In Rescue Vehicles 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17
... April 18, 2012  CAQH® announced today that ... the Universal Provider Datasource® (UPD®), demonstrating that ... standard for self-reported provider data used to ... network directories, referrals and claims administration. ...
... Live has revealed further details of the newest event ... (SEA) 2012. Set to debut from 10-12 May 2012 at ... first trade show and exhibition of its kind to be ... CPhI SEA will provide a meeting place ...
Cached Medicine Technology:One Million Healthcare Providers Now Use the CAQH Universal Provider Datasource 2One Million Healthcare Providers Now Use the CAQH Universal Provider Datasource 3Leading Pharma Ingredients Event Debuts in Growing ASEAN Market 2Leading Pharma Ingredients Event Debuts in Growing ASEAN Market 3
(Date:4/24/2014)... A national response to the epidemic of prescription opioid ... England Journal of Medicine by leaders of agencies ... The commentary calls upon health care providers to ... and reduce overdose deaths, and describes a number of ... medications. The commentary also discusses how medications can be ...
(Date:4/24/2014)... NH, 4/24/14) Dartmouth has been awarded one of ... serve as a Lead Academic Participating Site in its ... Award recipients are a select groups of investigators charged ... fewer cooperative groups., The NCTN grant system reflects recommendations ... It streamlines operations to achieve four goals:, ...
(Date:4/24/2014)... scientist at the University of York reveals that a ... of the nervous system may also play a pivotal ... research team, led by Dr Will Brackenbury, a Medical ... York, has studied how voltage-gated sodium channels assist in ... in the membranes of excitable cells, such as neurons, ...
(Date:4/23/2014)... for a new experimental drug to treat acute ... with CPX-351, a combination of the chemotherapeutic drugs ... patients treated with the standard drug formulation. ... aggressive blood cancer with very low rates of ... Lancet, M.D., senior member of the Department of ...
(Date:4/23/2014)... 23, 2014 The American Society for Radiation Oncology ... of Postoperative Radiation Therapy for Endometrial Cancer: An ... adjuvant radiation therapy in the treatment of endometrial ... the May-June 2014 issue of Practical Radiation ... of ASTRO. The full-length guideline is available as ...
Breaking Medicine News(10 mins):Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 2Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 3Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 4Health News:Dartmouth awarded lead role in NCI clinical trials network 2Health News:Dartmouth awarded lead role in NCI clinical trials network 3Health News:Breast cancer replicates brain development process 2Health News:Moffitt Cancer Center's phase 3 study may be game-changer for acute myeloid leukemia 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3
... done too soon can lead to respiratory trouble, other ... -- The rise in Caesarean deliveries could be fueling ... these early births carry risks, including respiratory problems, jaundice ... Tuesday during a March of Dimes conference in New ...
... been selected as the Grand Prize winner of the Jump Start ... ... Hudson, OH (PRWEB) December 18, 2008 -- A resident of ... the Jump Start ,09 national online sweepstakes sponsored by ActiveAmericans.com ...
... wellness center, will implement the C4 IP™ hosted VoIP and ... ... Atlanta, GA (PRWEB) December 18, 2008 -- ... implement the C4 IP™ hosted VoIP and ...
... recognize human gestures could provide a new way for ... related system for the able bodied could also be ... is described in detail in a forthcoming issue of ... , Manolya Kavakli of the Virtual and Interactive Simulations ...
... up after 3 years, study finds , , THURSDAY, Dec. 18 ... medication to prevent narrowing of the artery do better one ... stents, a new study shows. , However, within three years ... a greater risk of more surgery to increase blood flow ...
... Group-based treatment programs may effectively combat childhood obesity ... Florida study. , Children who participated in one of ... less overweight compared with children in a control group. ... Archives of Pediatric and Adolescent Medicine . , The ...
Cached Medicine News:Health News:Elective Early Deliveries Pose Risks for Babies 2Health News:Elective Early Deliveries Pose Risks for Babies 3Health News:Pittsburgh Area Resident Wins $15,000 In Online Sweepstakes 2Health News:MALO CLINIC Avoids Capital Expense and Gains Scalability with Hosted Unified Communications 2Health News:MALO CLINIC Avoids Capital Expense and Gains Scalability with Hosted Unified Communications 3Health News:MALO CLINIC Avoids Capital Expense and Gains Scalability with Hosted Unified Communications 4Health News:Gesture recognition 2Health News:Coated Stents Better Than Bare Metal Ones in Short Run 2Health News:Group treatment may help children achieve healthier weights 2Health News:Group treatment may help children achieve healthier weights 3
... in Canons DR innovations, the CXDI-31 is ... a compact and lightweight design, the Canon ... conventional screen-film cassettes. It is designed to ... to get with fixed devices and supports ...
... a cost-effective synthetic bone filler tailored ... Phosphate (TCP) and Hydroxyapatite (HAP), its ... BAB formulates the chemistry and microstructure ... This formulation provides optimal osteo-conduction. The ...
The Oscor PACE 101 H is an external single chamber cardiac demand pacemaker. The PACE 101 H feature an option for a atrial overdrive stimulation....
... TAU Lead is a ... stimulation lead for temporary ... The unique shaft design ... straight or preformed stylets ...
Medicine Products: